Open Access
ARTICLE
Angiogenic Gene PTK2 is a Potential Biomarker of Gestational Diabetes Mellitus and is Significantly Associated with Breast Cancer Immune Infiltration
Xuelian Du1,#, Hao Shi2,#, Haiyan Liu1, Linghua Zhou1, Anqun Xie1, Jufang Guo1,*
1
Department of Obstetrics and Gynecology, Jinniu District Maternal and Child Health Hospital, Chengdu, 610000, China
2
Department of Pediatrics, Jinniu District Maternal and Child Health Hospital, Chengdu, 610000, China
* Corresponding Author: Jufang Guo. Email:
# These authors contributed equally to this work and should be considered co-first authors
Oncologie 2022, 24(4), 769-787. https://doi.org/10.32604/oncologie.2022.026248
Received 26 August 2022; Accepted 24 October 2022; Issue published 31 December 2022
Abstract
Background: Gestational diabetes mellitus (GDM) affects the health of numerous women around the world. A
recent study has shown that GDM is associated with an increased incidence of cancer. In this study, we aimed
to explore the possible shared mechanisms and potential common therapeutic targets between GDM and cancer.
Methods: The limma package was used to identify differentially expressed genes (DEGs) in GDM. The Cytoscape
plugin cytoHubba was used to screen hub genes. The CIBERSORT algorithm was used to explore the correlation
between hub genes and immunity. Cox regression analysis was used to assess the relationship between protein
tyrosine kinase 2 (
PTK2) expression and prognosis in pan-cancer. Single-sample gene set enrichment analysis
(ssGSEA) and CIBERSORT were used to assess the correlation between
PTK2 and immunity in cancer. Mutation
and methylation analyses of
PTK2 were assessed using Spearman’s correlation test.
Results: A total of 871 DEGs
were identified, among which the hub genes were significantly highly expressed in GDM and had a strong association with immunity. Pan-cancer analysis revealed that
PTK2 was significantly overexpressed in multiple types
of cancer. Survival analysis showed that
PTK2 was significantly associated with poor prognosis in multiple cancers. Mutational analysis revealed that copy number variation of
PTK2 mediated abnormal expression of mRNA,
and expression of
PTK2 was significantly correlated with tumor mutational burden of various cancers. Immune
correlation analysis showed pre-correlation of
PTK2 with breast cancer, and patients with low expression of
PTK2
could benefit more from immunotherapy. GSEA enrichment analysis was enriched in adaptive immune response,
which verified the strong association of
PTK2 with immunity in breast cancer.
Conclusions: PTK2 was involved
in the immune response of GDM and breast cancer and may be a novel clinical prognostic marker and potential
common therapeutic target for GDM and breast cancer.
Keywords
Cite This Article
Du, X., Shi, H., Liu, H., Zhou, L., Xie, A. et al. (2022). Angiogenic Gene
PTK2 is a Potential Biomarker of Gestational Diabetes Mellitus and is Significantly Associated with Breast Cancer Immune Infiltration.
Oncologie, 24(4), 769–787. https://doi.org/10.32604/oncologie.2022.026248